BEIJING: A potential coronavirus vaccine developed by Chongqing Zhifei Biological Products has gotten approval by the Chinese government to begin human testing for determining its viability in curing Covid-19 patients. According to a company filing on Tuesday, June 23, the potential vaccine, co-developed by Anhui Zhifei Longcom Biopharmaceutical and the Institute of Microbiology, Chinese Academy of Sciences, has received a certificate from the National Medical Products Administration to launch clinical trials.
More than a dozen vaccines against the novel coronavirus are in trial stage across the world while Chinese researchers and companies are testing six experimental shots in humans. However, so far, none of them have passed large scale, late stage phase 3 clinical trials, a necessary step for proving that the vaccine is ready to enter the consumer market.